2016: Biotech’s Tumultuous Year

The video discusses the tumultuous biotech market, highlighting a 20% drop in the Nysdec biotech index despite a post-election bump. It explores the potential for drug companies to raise prices amid political pressure and the possibility of a tax holiday for overseas cash repatriation. Gilead's challenges in the hepatitis C market due to price competition and declining sales are examined, along with their public health initiatives. The impact of healthcare policies, such as Obamacare, on stocks is considered, with uncertainty around Trump's stance on drug pricing. Potential regulatory changes to speed up generic drug approvals are also discussed.

What challenges are drug companies facing in the current market?

What potential changes regarding drug pricing has Trump mentioned?